Backgrounds/Aims: It is important to point out that the identification of inflammation is an essential component of the pathogenesis and the progression of cancer. In this study, we analysed the neutrophil-to-lymphocyte ratio (NLR) and the platelets-to-lymphocyte ratio (PLR), with an overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC), who were treated with a resection following or not following a procedure of neoadjuvant chemotherapy/chemoradiation. We intended to identify the significance of the role of NLR and PLR, as prognostic markers in patients undergoing surgery for PDAC. Methods: There were 127 patients enrolled in the study. The NLR and PLR were calculated on the basis of the pre-treatment blood cell count. An NLR＞4 and a PLR ＞120 were considered to be elevated as measured. OS was analysed in relation to the NLR and PLR values, by using both the Kaplan-Meier and multivariate Cox-regression methods. Results: Both high the NLR and high PLR were associated with a decreased OS in the univariate analysis. In the multivariate analysis, the high NLR, but not the high PLR, was an independent predictor of a decreased OS. When we divided patients into three groups (group 1: normal both NLR and PLR, group 2: high NLR or high PLR, group 3: high both NLR and PLR), the three-years OS rates for these groups were 48%, 32%, 7% (p=0.001) respectively. Conclusions: It is noted that the pre-treatment NLR is an independent adverse prognostic factor, and considered to be superior to the PLR, in patients who undergo a resection for PDAC following or not neoadjuvant chemotherapy/chemoradiation. 
INTRODUCTION
Pancreatic cancer remains the fourth leading cause of death in relation to cancer worldwide, and it is noted with an overall 5-year survival rate that doesn't usually exceed 5%. 1 A high percentage of patients are diagnosed at a late stage with a median survival of five to six months in patients with the advanced stages of the disease. 2, 3 On the other hand, there is a variation in the biological behaviour of pancreatic cancer and a difference in survival rates among these patients, indicating the need for the identification of predictive markers to assist in the patient risk stratification and prognosis. This could lead to an improvement in patient selection for surgery and delineation of chemotherapeutic approach, which may improve patient outcomes going forward.
The inflammatory response in the patient plays a key role in the carcinogenesis process and tumour microenvironment, as initially described by Virchow in 1876. [4] [5] [6] [7] [8] A number of markers of inflammation and several ratios have been investigated in regards to their potential importance in prognosis and diagnosis in pancreatic cancer, as well as noted in other hepatobiliary malignancies including: C-reactive protein (CRP), the Modified Glasgow Prognostic Score, tumour necrosis factor (TNF)-, T lymphocytes recruitment and also neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] As international collaborative studies have previously addressed the development of an 'immunoscore' as a predictive form of a tumour's behaviour, 20, 21 the important role that prognostic markers and inflammation-based scores could potentially play is effortlessly highlighted for review below.
The aim of this study was to investigate the role of the pre-treatment NLR and PLR as well as their combination in the prediction of overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC), who are undergoing a resection with or without neoadjuvant chemotherapy/chemoradiation. 
MATERIALS AND METHODS

Statistical analyses
The primary end point of the study was OS. A NLR＞4
and a PLR ＞120 were considered to be elevated. Thhe 
RESULTS
A total of 127 patients were eligible for inclusion in the study. The consort diagram is presented in Fig. 1 Table   2 ).
We further divided the patients into three groups according to their NLR and PLR. The patients with normal both NLR and PLR were assigned to group 1, with high NLR or PLR assigned to group 2, and with high both NLR and PLR to group 3. This categorization was associated with decreased OS both in univariate analysis (p=0.001) and in multivariate analysis (p=0.005) ( Table   2 , Fig. 2 ). The patients in group 1 have the best OS while group 3 the worst. The patients in group 1 had a median OS of 35.5 months compared to a OS of 24.1 months for patients in group 2, and 17.1 months for patients in group 3. The 3-years OS rates for these groups (group 1, group 2, group 3) were 48%, 32%, 7% (p=0.001) respectively.
DISCUSSION
The inflammation and cancer are two entities that have been associated with each other and these links are under investigation via the analysis of the tumor microenvironment, the host's response, the inflammatory pathways and the chain of systemic effects. 8, 12 The role of the NLR has attracted a lot of attention the last years, with the incidence of an elevated NLR at different cancer stages reported to possess an ability to serve as a possible prognostic factor in several malignancies including colorectal cancer, hepatocellular carcinoma and pancreatic cancer. [22] [23] [24] [25] Our group has previously reported its prognostic value in patients with colorectal liver metastases. 26 On the other hand, the PLR is another ratio with potential prognostic values as demonstrated previously in different types of cancer including colorectal cancer, breast cancer and ovarian cancer. 9, 27, 28 Our group has also reported its significance as a prognostic tool in colorectal liver metastases as well. 29 The platelet's role in identifying the inflammatory processes is characterised by a review of the regulation of other types of cells such as neutrophils and facilitation of their adhesion to lymphocytes, and also by promoting the growth and spread of malignancies via onco-inflammatory mechanisms. 30, 31 We have demonstrated in this study that a pre-treatment NLR, but not a pre-treatment PLRm is an independent Additionally a Japanese group investigated the link between pre-treatment NLR and the pathological response to preoperative chemotherapy in pancreatic cancer patients, thereby concluding that the pre-treatment NLR is an independent predictive marker of the pathological response to preoperative therapy. 33 Similarly the Luo et al. We also demonstrated that high NLR was statistically significantly associated with positive lymph nodes following pancreatic resection. Notably, the MD Anderson group have previously highlighted the significance of the number and ratio of positive lymph nodes on pancreatic cancer patient survival after neoadjuvant chemotherapy and pancreaticoduodenectomy. 35 The significance of positive lymph nodes has also been emphasized by other authors, and we agree with these recommendations. [36] [37] [38] We dem- In the multivariate analysis, the only factors which remained statistically associated with OS was a R1 resection where it was demonstrated that an elevated NLR is superior to a PLR for prognostication in patients with pancreatic cancer and with PLR not having independent prognostic value but elevated NLR being associated with higher PLR. 39 Additionally the Garcea et al. 40 In conclusion we have indicated that the pre-treatment NLR is an independent adverse prognostic factor in patients who undergo resection for PDAC, following or not 
